Sugemalimab vs Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-L1 · full Non-Small Cell Lung Cancer pipeline

Sugemalimab · Cejemly

Marketed by CStone Pharmaceuticals and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT03728556 · Phase 3 · completed

In this randomized, quadruple-blind, placebo-controlled Phase 3 trial, 381 patients with stage III lung cancer who had completed chemoradiotherapy were randomized to sugemalimab or placebo. Sugemalimab significantly reduced the risk of progression or death compared with placebo (median progression-free survival 10.5 vs 6.2 months).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: May 2027 · NCT07247227 (registry estimate)

Reported efficacy

Progress Free Survival (PFS) (from the date of randomization to the first date of recorded progression or all-cause death, whichever comes first, assessed up to 30 months.): Progression-free survival (BICR-assessed), GEMSTONE-301: median PFS 10.5 months (sugemalimab) vs 6.2 months (placebo); HR 0.65, 95% CI 0.50-0.84 (met)

Result source: NCT03728556

Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)

Marketed by Roche

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03735121 · Phase 3 · completed

This was a randomized, open-label, active-controlled phase 3 study comparing subcutaneous atezolizumab with the established IV formulation in previously treated NSCLC. The primary endpoints were pharmacokinetic measures (serum trough concentration and AUC) rather than clinical outcomes, and the non-inferiority comparisons were met for both. Because the study was open-label and the primary endpoints were surrogate PK measures, the evidence is limited despite the randomized design and adequate sample size.

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSugemalimabTecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
PFS, median10.5 vs 6.2a+4.3 vs placeboNCT03728556—Not reported
OS, median—Not posted · NCT03728556—Not reported
ORR—Not posted · NCT03728556—Not reported
Duration of response, median—Not posted · NCT03728556—Not reported

PFS, median

Sugemalimab
10.5 vs 6.2a+4.3 vs placeboNCT03728556
Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
—Not reported

OS, median

Sugemalimab
—Not posted · NCT03728556
Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
—Not reported

ORR

Sugemalimab
—Not posted · NCT03728556
Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
—Not reported

Duration of response, median

Sugemalimab
—Not posted · NCT03728556
Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
—Not reported
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs): registry results are on file for Non-Small Cell Lung Cancer, but their comparison mappings are not yet available.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Sugemalimab

PFS 10.5 vs 6.2 placebo months
time to event · months
NCT03728556 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Sugemalimab's landscape · Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)'s landscape